Indivior's shares plunged 80% after a US federal grand jury indicted the UK drugmaker for misleading doctors and public-health officials about the benefits of Suboxone Film, its blockbuster opioid-addiction treatment.
Indivior plans to"vigorously contest" the charges and considers them to be"wholly unsupported by either the facts or the law." Shares of Indivior plummeted 80% in Wednesday morning after the US Justice Department accused the British drugmaker of making billions of dollars by lying about the benefits of a blockbuster drug-addiction treatment, leading thousands of opioid-addicted patients to use the drug.
"Our indictment alleges a wide-ranging and truly shameful scheme to put profits over the health and well-being of patients trying to manage substance use disorder and opioid dependence,""It's incredibly frustrating that while we have been working to remove the stigma around medication-assisted treatment and make it more widely available, Indivior was allegedly conspiring to exploit patients, taxpayers, and the expansion of [medication-assisted treatment].